Welgene Biotech Co.,Ltd. (6661.TWO)

TWD 23.6

(0.85%)

Net Debt Summary of Welgene Biotech Co.,Ltd.

Welgene Biotech Co.,Ltd.'s latest annual net debt in 2023 was -33.78 Million TWD , up 68.54% from previous year.
Welgene Biotech Co.,Ltd.'s latest quarterly net debt in 2024 Q2 was -16.56 Million TWD , up 42.09% from previous quarter.
Welgene Biotech Co.,Ltd. reported annual net debt of -107.4 Million TWD in 2022, up 38.95% from previous year.
Welgene Biotech Co.,Ltd. reported annual net debt of -175.92 Million TWD in 2021, down -34.34% from previous year.
Welgene Biotech Co.,Ltd. reported quarterly net debt of -16.56 Million TWD for 2024 Q2, up 42.09% from previous quarter.
Welgene Biotech Co.,Ltd. reported quarterly net debt of -33.78 Million TWD for 2023 FY, up 68.54% from previous quarter.

Annual Net Debt Chart of Welgene Biotech Co.,Ltd. (2023 - 2014)

Historical Annual Net Debt of Welgene Biotech Co.,Ltd. (2023 - 2014)

Year	Net Debt	Net Debt Growth
2023	-33.78 Million TWD	68.54%
2022	-107.4 Million TWD	38.95%
2021	-175.92 Million TWD	-34.34%
2020	-130.95 Million TWD	-3.12%
2019	-126.99 Million TWD	-0.23%
2018	-126.7 Million TWD	-24.97%
2017	-101.38 Million TWD	4.28%
2016	-105.92 Million TWD	-23.21%
2015	-85.96 Million TWD	-81.51%
2014	-47.36 Million TWD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	-27.39 Million TWD	18.92%
2024 Q2	-16.56 Million TWD	42.09%
2023 FY	-33.78 Million TWD	68.54%
2023 Q3	31.97 Million TWD	128.51%
2023 Q4	-33.78 Million TWD	-205.65%
2023 Q1	-102.27 Million TWD	4.78%
2023 Q2	13.99 Million TWD	113.68%
2022 Q3	-175.57 Million TWD	-33.83%
2022 Q2	-131.19 Million TWD	-11.57%
2022 Q1	-117.58 Million TWD	33.16%
2022 FY	-107.4 Million TWD	38.95%
2022 Q4	-107.4 Million TWD	38.83%
2021 Q1	-188.23 Million TWD	-43.74%
2021 Q3	-122.79 Million TWD	0.77%
2021 Q4	-175.92 Million TWD	-43.26%
2021 FY	-175.92 Million TWD	-34.34%
2021 Q2	-123.75 Million TWD	34.26%
2020 Q4	-130.95 Million TWD	-28.62%
2020 FY	-130.95 Million TWD	-3.12%
2020 Q3	-101.81 Million TWD	15.96%
2020 Q2	-121.15 Million TWD	-163.01%
2020 Q1	192.28 Million TWD	251.42%
2019 Q2	-139.52 Million TWD	0.0%
2019 Q1	-139.52 Million TWD	-10.13%
2019 FY	-126.99 Million TWD	-0.23%
2019 Q4	-126.99 Million TWD	0.0%
2018 Q4	-126.7 Million TWD	0.0%
2018 FY	-126.7 Million TWD	-24.97%
2018 Q1	-90.39 Million TWD	10.84%
2018 Q2	-90.39 Million TWD	0.0%
2018 Q3	-126.7 Million TWD	-40.17%
2017 Q2	-84.69 Million TWD	3.26%
2017 Q1	-87.55 Million TWD	17.34%
2017 Q4	-101.38 Million TWD	4.14%
2017 Q3	-105.76 Million TWD	-24.88%
2017 FY	-101.38 Million TWD	4.28%
2016 FY	-105.92 Million TWD	-23.21%
2016 Q4	-105.92 Million TWD	4.07%
2016 Q3	-110.41 Million TWD	0.0%
2015 FY	-85.96 Million TWD	-81.51%
2014 FY	-47.36 Million TWD	0.0%

Peer Net Debt Comparison of Welgene Biotech Co.,Ltd.

Name	Net Debt	Net Debt Difference
BIONET Corp.	-193.47 Million TWD	82.539%
DIVA Laboratories, Ltd.	-534.39 Million TWD	93.678%
Genetics Generation Advancement Corp.	-79.18 Million TWD	57.336%
Puriblood Medical Co., Ltd.	-65.84 Million TWD	48.69%
TFBS Bioscience Inc.	-797.57 Million TWD	95.764%